- Home
- ENLV vs APVO Comparison
ENLV vs APVO Comparison
Compare ENLV & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- APVO
- Stock Information
- Founded
- ENLV 2005
- APVO 2016
- Country
- ENLV Israel
- APVO United States
- Employees
- ENLV N/A
- APVO N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- ENLV Health Care
- APVO Health Care
- Exchange
- ENLV Nasdaq
- APVO Nasdaq
- Market Cap
- ENLV 26.6M
- APVO 21.7M
- IPO Year
- ENLV 1995
- APVO N/A
- Fundamental
- Price
- ENLV $1.06
- APVO $1.52
- Analyst Decision
- ENLV Strong Buy
- APVO
- Analyst Count
- ENLV 2
- APVO 0
- Target Price
- ENLV $10.00
- APVO N/A
- AVG Volume (30 Days)
- ENLV 180.4K
- APVO 4.6M
- Earning Date
- ENLV 11-28-2025
- APVO 11-10-2025
- Dividend Yield
- ENLV N/A
- APVO N/A
- EPS Growth
- ENLV N/A
- APVO N/A
- EPS
- ENLV N/A
- APVO N/A
- Revenue
- ENLV N/A
- APVO N/A
- Revenue This Year
- ENLV N/A
- APVO N/A
- Revenue Next Year
- ENLV N/A
- APVO N/A
- P/E Ratio
- ENLV N/A
- APVO N/A
- Revenue Growth
- ENLV N/A
- APVO N/A
- 52 Week Low
- ENLV $0.81
- APVO $1.32
- 52 Week High
- ENLV $2.10
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- ENLV 47.24
- APVO 44.41
- Support Level
- ENLV $1.04
- APVO $1.48
- Resistance Level
- ENLV $1.10
- APVO $1.65
- Average True Range (ATR)
- ENLV 0.05
- APVO 0.13
- MACD
- ENLV -0.00
- APVO 0.01
- Stochastic Oscillator
- ENLV 22.22
- APVO 6.10
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.